Fierce Biotech May 3, 2024
CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company’s Wall Street success story is no fluke.
The oncolytic-virus-based therapeutic company reported Friday that cretostimogene elicited a 75.2% complete response rate in a late-stage trial among 105 evaluable patients with non-muscle invasive bladder cancer (NMIBC).
The data reported at the American Urological Association annual meeting found that none of the patients reporting a complete response had to get their bladder removed and that 29 patients maintained a complete response for at least a year, with 22 more patients pending evaluation. The median duration of response has not yet been reached as of the April 1 data cutoff, with...
Today's Sponsors
Today's Sponsor